β-Adrenoceptor Drugs and Parkinson’s Disease: A Nationwide Nested Case–Control Study

Germay, Sibylle de; Conte, Cécile; Rascol, Olivier; Montastruc, Jean‐Louis; Lapeyre‐Mestre, Maryse

doi:10.1007/s40263-020-00736-2

Cited by 13 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a French nested case–control study, β2AR agonist exposure was associated with a reduced risk of PD only in the population without diabetes. Conversely, increased risk of PD was found in patients with diabetes who were exposed to a β2AR agonist [ 20 ]. Several studies have suggested that type 2 diabetes is associated with an increased risk of PD [ 23 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background and Objective: Parkinson’s disease (PD) is a progressive neurological disorder characterized by an accumulation of Lewy bodies and degeneration of dopaminergic neurons in the substantia nigra. The treatment options currently available are only partly effective and fail to restore the lost dopaminergic neurons or slow the progression. β2-adrenoceptors (β2AR) are widely expressed in various human tissues and organs, regulate many important metabolic functions, and are targeted for treatment of various diseases. Studies have reported a link between chronic use of the β2AR antagonist propranolol and an increased risk of PD, and chronic use of β2AR agonists has been associated with a decreased risk of PD. We conducted a meta-analysis on the association between both β2AR agonist level and β2AR antagonist level and the risk of PD. Materials and Methods: A comprehensive electronic search was conducted on the databases of PubMed, ScienceDirect, ProQuest, Cochrane Library, and ClinicalKey from the start of each database until 30 June 2021. The objective was to identify prospective cohort and case–control studies that have reported on the association between β-adrenoceptor agonist level, antagonist level, and PD risk. Results: A meta-analysis of the data extracted from eight studies revealed that β2AR agonist use was associated with reduced PD risk (RR = 0.859, 95% confidence interval [CI] 0.741–0.995. p = 0.043). Compared with the control group, β2AR antagonist use was associated with an increased risk of PD (RR = 1.490, 95% CI, 1.195 to 1.857. p < 0.005). Propranolol, a type of β2AR antagonist, was related to an increased risk of PD (RR = 2.820, 95% CI, 2.618 to 3.036. p < 0.005). Conclusions: In this meta-analysis, β2AR agonists were associated with a decreased risk of PD, and β2AR antagonists were related with an increased risk of PD. However, further studies with larger sample sizes and an evaluation of the long-term effects of varying dosages of medications are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…El uso de propranolol se ha asociado con un mayor riesgo de EP 21,22 . Curiosamente, un estudio reciente informó un efecto protector de los betabloqueadores en la aparición de EP en pacientes no diabéticos, pero lo contrario en pacientes diabéticos con EP 23 .…”

Section: Discussionunclassified

“…La salvedad más notable de estos estudios es que las personas con peso normal y bajo peso se agruparon, por lo que no fue posible evaluar el bajo peso como un posible factor de riesgo independiente. Un estudio sobre este tema que utilizó una base de datos nacional coreana encontró un riesgo de 1.28 para la EP en el grupo con bajo peso, en comparación con sujetos con IMC normal 23 . Por otro lado, el mismo estudio informó un posible efecto protector para el grupo con sobrepeso, similar a nuestros hallazgos.…”

Section: Discussionunclassified

Asociación entre comorbilidades cardiometabólicas y enfermedad de Parkinson en población mexicana

Cervantes-Arriaga¹,

Esquivel-Zapata²,

Escobar-Valdivia³

et al. 2021

GMM

View full text Add to dashboard Cite

“…5 Recent in vitro and animal model studies have found associations of beta-adrenoreceptor with neuronal SNCA expression and demonstrated a regulatory action of the SNCA through beta-adrenoceptor activation. 1,6 This evidence has been strengthened by recent observational studies that investigated the association between beta-adrenoceptors (agonists and antagonists) exposure and PD onset. 7-9 The study results demonstrated that the chronic use of the beta-adrenoceptor antagonist (propranolol) was associated with an increased risk of PD, while the chronic use of the beta-adrenoceptor agonists (salbutamol) was associated with a decreased risk.…”

Section: Background and Rationalementioning

confidence: 94%

“…PD is characterized by the cardinal features of rest tremor, bradykinesia, rigidity, postural instability, and a variety of other motor and non-motor symptoms. 1,2 Globally, an estimated 9.4 million people live with PD. With an aging population, the prevalence and incidence of PD are expected to increase by >30% by 2030, contributing to a significant humanistic and economic burden globally.…”

Section: Background and Rationalementioning

confidence: 99%

Systematic Review and Meta-Analysis Protocol: Beta adrenoreceptor drugs and risk of Parkinson’s disease

Singh¹,

Hussain

Akkala

et al. 2021

Preprint

View full text Add to dashboard Cite

Parkinsons disease (PD) is a progressive nervous system disorder characterised by the loss of dopaminergic neurons leading to motor and non-motor symptoms. Accumulation of α-synuclein protein (SNCA) in the form of Lewy bodies has been observed in dopaminergic neurons of PD patients. Potential relationships between β-adrenergic drugs (agonists and antagonist) and SNCA synthesis in PD have been recently suggested. This study aims to systematically review the evidence from various epidemiological studies that analysed the association between beta-adrenoceptors (agonists and antagonists) and the risk of PD. Biomedical databases such as PubMed and Embase will be searched to identify the individual studies that reported the relationship between beta-adrenoceptors and the risk of PD. JBI critical appraisal tool scale will be used to assess the quality of included studies. The primary outcome will be to compute the pooled risk of PD among beta-agonist and antagonist users. Furthermore, we will consider the pooled risk of PD based on study design, types of beta-agonist or antagonist exposure under secondary outcomes. RevMan 5, STATA 16, and ProMeta 3.0 will be used to conduct the statistical analysis.

show abstract

β-Adrenoceptor Drugs and Parkinson’s Disease: A Nationwide Nested Case–Control Study

Cited by 13 publications

References 30 publications

Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis

Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis

Asociación entre comorbilidades cardiometabólicas y enfermedad de Parkinson en población mexicana

Systematic Review and Meta-Analysis Protocol: Beta adrenoreceptor drugs and risk of Parkinson’s disease

Contact Info

Product

Resources

About